News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AVANIR Pharmaceuticals (AVNR) Presents Data At American Neurological Association Annual Meeting


9/24/2008 10:00:29 AM

ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced the presentation of two posters at the American Neurological Association’s 133rd Annual Meeting in Salt Lake City. The posters covered the results of the pharmacokinetic/pharmacodynamic (PK/PD) modeling that was used to predict the safety and efficacy of the new lower dose formulation of Zenvia™ (dextromethorphan/quinidine [DM/Q]) now being tested in the ongoing STAR Phase III trial, as well as the impact of pseudobulbar affect (PBA) on caregivers.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES